New portfolio for imaging systems could reduce impact on patient care.
Institutions with Siemens Healthineers products can now select a service contract option that best matches their operational schedule, limiting the impact of routine maintenance on patient care activities.
With CentriCare – a new, patient-centric service contract portfolio – Siemens allows customers to select the most convenient time period for company personnel to address non-urgent service requests. Doing so addresses the issue of existing service contracts frequently overlapping with operational hours, the company said. It's a problem that can result in preventive maintenance infringing on patient care.
According to a press statement, CentriCare offers three flexible service plans – Signature, Benchmark, and Balance – that offer more system availability and uptime while limitng clinical disruption during time periods where machines are needed most for patient care.
“Customers have asked us to align with their priorities so that they can provide an optimal patient experience free of offline imaging systems and extended patient wait times. These customers also want to avoid related out-of-scope service expenses, such as overtime, spare parts, and expediated shipping charges,” said Michael Wendt, senior vice president of customer services at Siemens Healthineers, in the written statement. “The CentriCare service portfolio is a direct response to these customer requests.”
Each plan offers Protected Care Hours during which Siemens guarantees 100-percent uptime, according to the company statement. But, if service-hour interruptions do occur, the CentriCare Entrust Program offers per-hour credits that can be applied to current or future invoices for other Siemens products and services. Other CentriCare components can include single vendor point-of-contact, including dedicated VIP phone line or a clinical or technical concierge expert, to help with onboarding to service escalations and incident reporting.
Currently, CentriCare service contracts are available in certain parts of the United States, including the Northeast.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.